HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TYK MEDICINES-B

2.680

-0.770-22.32%

Volume:7.77M

Turnover:22.76M

Market Cap:1.02B

PE:-2.87

High:3.550

Open:3.550

Low:2.615

Close:3.450

52wk High:22.560

52wk Low:2.615

Shares:380.07M

HK Float Shares:375.46M

Volume Ratio:0.98

T/O Rate:2.07%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.935

ROE:-70.66%

ROA:-28.19%

PB:3.34

PE(LYR):-2.87

PS:8142.22

Loading ...

Overview Company News Filings

Major Breakthrough at ASCO 2026: TYK MEDICINES-B's Edotinib Achieves 95.5% Intracranial Objective Response Rate, Leading the Frontline Treatment for EGFR Lung Cancer Brain Metastases

TYK Medicines reports superior interim Phase II data for asandeutertinib versus osimertinib in first-line EGFR-mutant NSCLC with brain metastases

Bulletin Express

Key Phase II ESAONA Study Results for TYK MEDICINES-B's (02410) TY-9591 in First-Line NSCLC Brain Metastases Presented as Late-Breaking Abstract at 2026 ASCO

TYK Medicines says Phase II study shows asandeutertinib beats osimertinib on intracranial response in EGFR-mutant NSCLC with brain metastases

TYK Medicines Releases 2025 AGM Agenda Covering Profit Distribution, Share Mandates and Board Re-election

Bulletin Express

TYK Medicines to Seek 20% Share Issue Mandate, RMB300 Million Bank Lines and No-Dividend Plan at 23 June AGM

Bulletin Express

Insiders Could Have Profited By Holding onto TYK Medicines Shares Despite 12% Drop

Simply Wall St.

TYK Medicines Posts Stable Share Capital and Maintains Public Float in April 2026 Monthly Return

Bulletin Express

TYK Medicines-B 2025年研发推进加速，亏损收窄至3.06亿元，净资产维持正值

Bulletin Express

TYK Medicines publishes 2025 annual report

TYK MEDICINES-B's (02410) Self-Developed TY-3002 Monotherapy Demonstrates Outstanding Weight Loss Efficacy, Pioneering Next-Generation Oral GLP-1R Small Molecule Innovation

TYK Medicines Converts 4.61 Million Unlisted Shares Into H Shares, Registered Capital Rises to RMB 380.07 Million

Bulletin Express

TYK Medicines Completes 4.61 Million-Share Conversion to H Shares, Expanding Registered Capital to 380.07 Million

Bulletin Express

Stock Track | TYK MEDICINES-B Soars 7.26% Intraday on Strong Annual Results and Upcoming AACR Presentation

TYK MEDICINES-B Shares Surge Over 7% Following Annual Report and Key AACR Presentation Announcement

TYK Medicines' Loss Narrows in 2025

MT Newswires Live

BRIEF-Tyk Medicines FY Loss Attributable Rmb299.8 Million

TYK MEDICINES-B Reports Annual Results: R&D Expenditure Rises 3.7% to Approximately 244 Million Yuan

TYK Medicines 2025 Net Loss Narrows 21% to RMB 305.97 Million; NDA for Core Drug TY-9591 Enters Priority Review

Bulletin Express

Tyk Medicines Inc - FY Loss Attributable RMB299.8 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/02410/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02410","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02410\",,,,,undefined,":{"symbol":"02410","market":"HK","secType":"STK","nameCN":"TYK MEDICINES-B","latestPrice":2.68,"timestamp":1789027724000,"preClose":3.45,"halted":0,"volume":7767000,"delay":0,"changeRate":-0.22318840579710145,"floatShares":375457818,"shares":380065818,"eps":-0.9353135831124635,"marketStatus":"Closed","change":-0.77,"latestTime":"09-10 16:08:44","open":3.55,"high":3.55,"low":2.615,"amount":22756187,"amplitude":0.271014,"askPrice":2.68,"askSize":295500,"bidPrice":2.675,"bidSize":7000,"shortable":3,"etf":0,"ttmEps":-0.6564907582767436,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":5,"adr":0,"listingDate":1724083200000,"exchange":"SEHK","adjPreClose":3.45,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"volumeRatio":0.982993,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02410\",,,,,undefined,":{"symbol":"02410","floatShares":375457818,"roa":"-28.19%","roe":"-70.66%","lyrEps":-0.935314,"volumeRatio":0.982993,"shares":380065818,"dividePrice":0,"high":3.55,"amplitude":0.271014,"preClose":3.45,"low":2.615,"week52Low":2.615,"pbRate":"3.34","psRate":"8142.22","week52High":22.56,"institutionHeld":0,"latestPrice":2.68,"committee":-0.953719,"eps":-0.9353135831124635,"divideRate":0,"volume":7767000,"delay":0,"ttmEps":-0.6564907582767436,"open":3.55,"prevYearClose":13.11,"prevWeekClose":6.205,"prevMonthClose":5.56,"prevQuarterClose":5.73,"fiveDayClose":6.065,"twentyDayClose":6.85,"sixtyDayClose":6.44},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02410\",params:#limit:5,,,undefined,":[{"date":"2026-08-17","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1786930200000,"name":null,"time":"","dateTimestamp":1786896000000,"actualEps":null},{"date":"2026-03-30","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null},{"date":"2025-08-31","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756603800000,"name":null,"time":"","dateTimestamp":1756569600000,"actualEps":null},{"date":"2025-03-27","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743039000000,"name":null,"time":"","dateTimestamp":1743004800000,"actualEps":null},{"date":"2024-08-30","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724981400000,"name":null,"time":"","dateTimestamp":1724947200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02410\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02410\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02410\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02410","date":"2026-09-09","current":-4.082312,"percent":1,"low":-45.171338,"twenty":-23.850097,"median":-16.983362,"eighty":-11.991643,"high":-5.344387,"avg":-17.864597,"sd":7.240648,"marketCap":1327124672},"quantilePoints":[{"date":"2024-08-23","current":-18.036629,"twenty":-16.647141,"median":-14.72623,"eighty":-12.008468,"marketCap":8010053668},{"date":"2024-08-30","current":-17.916348,"twenty":-18.108709,"median":-17.490261,"eighty":-14.277882,"marketCap":8010053668},{"date":"2024-09-06","current":-22.38992,"twenty":-20.387629,"median":-17.957821,"eighty":-15.985061,"marketCap":10531737231},{"date":"2024-09-13","current":-25.215246,"twenty":-24.52304,"median":-18.767123,"eighty":-16.911292,"marketCap":11829662594},{"date":"2024-09-20","current":-22.432724,"twenty":-24.518581,"median":-20.496807,"eighty":-17.208183,"marketCap":10587362603},{"date":"2024-09-27","current":-24.719835,"twenty":-24.497927,"median":-22.38992,"eighty":-17.671485,"marketCap":11736953639},{"date":"2024-10-04","current":-24.95032,"twenty":-24.87878,"median":-23.321155,"eighty":-17.932937,"marketCap":11792579012},{"date":"2024-10-10","current":-25.38933,"twenty":-24.941363,"median":-23.362473,"eighty":-17.973583,"marketCap":11922371548},{"date":"2024-10-18","current":-26.355956,"twenty":-25.311733,"median":-23.798709,"eighty":-18.108709,"marketCap":12311749157},{"date":"2024-10-25","current":-24.571342,"twenty":-25.374683,"median":-24.122054,"eighty":-18.545067,"marketCap":11477368567},{"date":"2024-11-01","current":-18.445843,"twenty":-25.311733,"median":-23.998666,"eighty":-18.584118,"marketCap":8621932768},{"date":"2024-11-08","current":-20.323115,"twenty":-25.278482,"median":-23.623818,"eighty":-17.973583,"marketCap":9456313359},{"date":"2024-11-15","current":-19.45318,"twenty":-25.171449,"median":-23.425489,"eighty":-18.108709,"marketCap":8955685004},{"date":"2024-11-22","current":-24.620137,"twenty":-24.988066,"median":-23.362473,"eighty":-18.406793,"marketCap":11329034239},{"date":"2024-11-29","current":-31.047836,"twenty":-25.311733,"median":-23.554037,"eighty":-18.584118,"marketCap":14277178993},{"date":"2024-12-06","current":-34.758675,"twenty":-25.786797,"median":-23.737743,"eighty":-19.168188,"marketCap":15945940174},{"date":"2024-12-13","current":-35.961329,"twenty":-26.0415,"median":-24.070769,"eighty":-19.324298,"marketCap":16465110319},{"date":"2024-12-20","current":-44.500897,"twenty":-30.298107,"median":-24.44033,"eighty":-19.494791,"marketCap":20284719244},{"date":"2024-12-27","current":-43.273475,"twenty":-31.455257,"median":-24.553474,"eighty":-19.619623,"marketCap":19709923726},{"date":"2025-01-03","current":-39.042242,"twenty":-33.760908,"median":-24.669986,"eighty":-19.709581,"marketCap":17800119264},{"date":"2025-01-10","current":-16.73771,"twenty":-34.083555,"median":-24.719835,"eighty":-19.709581,"marketCap":7602134269},{"date":"2025-01-17","current":-16.071561,"twenty":-33.760908,"median":-24.553474,"eighty":-18.860667,"marketCap":7305465614},{"date":"2025-01-24","current":-20.268382,"twenty":-32.413923,"median":-24.349989,"eighty":-19.230133,"marketCap":9270895450},{"date":"2025-01-28","current":-18.549699,"twenty":-31.591026,"median":-24.122054,"eighty":-18.549699,"marketCap":8529223814},{"date":"2025-02-07","current":-17.965815,"twenty":-31.472067,"median":-23.871541,"eighty":-18.275892,"marketCap":8214013368},{"date":"2025-02-14","current":-19.878813,"twenty":-31.451054,"median":-23.623818,"eighty":-18.275892,"marketCap":9066935750},{"date":"2025-02-21","current":-25.066745,"twenty":-31.047836,"median":-23.789321,"eighty":-18.32609,"marketCap":11495910358},{"date":"2025-02-28","current":-26.244856,"twenty":-30.411824,"median":-23.765234,"eighty":-18.39703,"marketCap":11996538712},{"date":"2025-03-07","current":-24.725844,"twenty":-30.135297,"median":-23.927628,"eighty":-18.445843,"marketCap":11347576030},{"date":"2025-03-14","current":-23.101371,"twenty":-29.84324,"median":-23.977848,"eighty":-18.549699,"marketCap":10605904394},{"date":"2025-03-21","current":-22.868028,"twenty":-28.789228,"median":-23.789321,"eighty":-18.691799,"marketCap":10494653649},{"date":"2025-03-28","current":-28.703724,"twenty":-28.703724,"median":-23.977848,"eighty":-19.110968,"marketCap":13146129748},{"date":"2025-04-03","current":-29.204856,"twenty":-29.744706,"median":-24.122054,"eighty":-19.131966,"marketCap":12070705875},{"date":"2025-04-11","current":-24.387234,"twenty":-29.307899,"median":-24.067881,"eighty":-19.145106,"marketCap":10012567086},{"date":"2025-04-17","current":-24.599189,"twenty":-28.955479,"median":-24.067881,"eighty":-19.224594,"marketCap":10123817831},{"date":"2025-04-25","current":-24.758022,"twenty":-28.755026,"median":-24.236021,"eighty":-19.282593,"marketCap":10197984995},{"date":"2025-05-02","current":-30.859428,"twenty":-28.772127,"median":-24.368612,"eighty":-19.308976,"marketCap":12738210348},{"date":"2025-05-09","current":-26.222368,"twenty":-28.789228,"median":-24.487968,"eighty":-19.376573,"marketCap":11477368567},{"date":"2025-05-16","current":-19.875071,"twenty":-28.703724,"median":-24.44033,"eighty":-19.45318,"marketCap":8770267095},{"date":"2025-05-23","current":-18.391406,"twenty":-28.460584,"median":-24.320388,"eighty":-19.147078,"marketCap":8139846205},{"date":"2025-05-30","current":-16.767615,"twenty":-28.328721,"median":-24.116277,"eighty":-18.777931,"marketCap":7453799941},{"date":"2025-06-06","current":-19.720458,"twenty":-27.077703,"median":-23.93026,"eighty":-18.847277,"marketCap":8788808886},{"date":"2025-06-13","current":-16.18601,"twenty":-26.697665,"median":-23.850097,"eighty":-18.709822,"marketCap":7216465018},{"date":"2025-06-20","current":-14.05098,"twenty":-26.664525,"median":-23.778892,"eighty":-18.426653,"marketCap":6252291891},{"date":"2025-06-27","current":-16.3221,"twenty":-26.630078,"median":-23.66211,"eighty":-18.32609,"marketCap":7283215465},{"date":"2025-07-04","current":-17.493079,"twenty":-26.41078,"median":-23.623818,"eighty":-18.194509,"marketCap":7806093968},{"date":"2025-07-11","current":-16.487526,"twenty":-26.267076,"median":-23.430941,"eighty":-17.964216,"marketCap":7349965912},{"date":"2025-07-18","current":-15.867745,"twenty":-26.226866,"median":-23.321155,"eighty":-17.866761,"marketCap":7068130691},{"date":"2025-07-25","current":-16.407488,"twenty":-26.143659,"median":-23.070409,"eighty":-17.335488,"marketCap":7335132480},{"date":"2025-08-01","current":-14.539711,"twenty":-26.072617,"median":-22.868028,"eighty":-17.325642,"marketCap":6459959949},{"date":"2025-08-08","current":-15.316665,"twenty":-25.987382,"median":-22.563641,"eighty":-17.04089,"marketCap":6822181433},{"date":"2025-08-15","current":-17.450454,"twenty":-25.968574,"median":-22.406203,"eighty":-16.915178,"marketCap":7760944003},{"date":"2025-08-22","current":-13.484776,"twenty":-25.95357,"median":-22.354126,"eighty":-16.718364,"marketCap":5978435317},{"date":"2025-08-29","current":-12.516323,"twenty":-25.925655,"median":-21.46252,"eighty":-16.486483,"marketCap":5575565550},{"date":"2025-09-05","current":-19.23268,"twenty":-25.919389,"median":-21.226743,"eighty":-16.486483,"marketCap":5883418862},{"date":"2025-09-12","current":-18.156363,"twenty":-25.850806,"median":-20.678772,"eighty":-16.541494,"marketCap":5564163575},{"date":"2025-09-19","current":-18.839434,"twenty":-25.807696,"median":-20.500943,"eighty":-16.56352,"marketCap":5769399117},{"date":"2025-09-26","current":-19.348832,"twenty":-25.743581,"median":-20.268382,"eighty":-16.654406,"marketCap":5910023469},{"date":"2025-10-03","current":-22.468168,"twenty":-25.650075,"median":-20.314843,"eighty":-16.707921,"marketCap":6879191305},{"date":"2025-10-10","current":-19.927643,"twenty":-25.596841,"median":-20.323115,"eighty":-16.732368,"marketCap":6092455062},{"date":"2025-10-17","current":-19.134493,"twenty":-25.519561,"median":-20.155539,"eighty":-16.749672,"marketCap":5845412280},{"date":"2025-10-24","current":-17.635142,"twenty":-25.404318,"median":-19.980008,"eighty":-16.781291,"marketCap":5389333299},{"date":"2025-10-31","current":-19.024541,"twenty":-25.400784,"median":-19.927643,"eighty":-16.830147,"marketCap":5822608331},{"date":"2025-11-07","current":-17.694439,"twenty":-25.37593,"median":-19.869193,"eighty":-16.945559,"marketCap":5412137248},{"date":"2025-11-14","current":-17.099248,"twenty":-25.321084,"median":-19.741813,"eighty":-16.951188,"marketCap":5244908288},{"date":"2025-11-21","current":-15.19815,"twenty":-25.311733,"median":-19.694587,"eighty":-16.919035,"marketCap":4659606928},{"date":"2025-11-28","current":-16.711808,"twenty":-25.293455,"median":-19.641679,"eighty":-16.730587,"marketCap":5142290517},{"date":"2025-12-05","current":-17.262657,"twenty":-25.275139,"median":-19.635782,"eighty":-16.587841,"marketCap":5320921452},{"date":"2025-12-12","current":-16.160016,"twenty":-25.213434,"median":-19.544821,"eighty":-16.497144,"marketCap":4990264190},{"date":"2025-12-19","current":-16.355316,"twenty":-25.19336,"median":-19.414876,"eighty":-16.454475,"marketCap":5062476695},{"date":"2025-12-24","current":-15.692499,"twenty":-25.154877,"median":-19.348832,"eighty":-16.406101,"marketCap":4872443786},{"date":"2026-01-02","current":-15.765099,"twenty":-25.10227,"median":-19.292077,"eighty":-16.35327,"marketCap":4914251026},{"date":"2026-01-09","current":-17.392186,"twenty":-25.070347,"median":-19.235279,"eighty":-16.345574,"marketCap":5434941197},{"date":"2026-01-16","current":-16.438751,"twenty":-25.06473,"median":-19.137216,"eighty":-16.35327,"marketCap":5153692492},{"date":"2026-01-23","current":-15.75073,"twenty":-25.023112,"median":-19.120814,"eighty":-16.314941,"marketCap":4933254317},{"date":"2026-01-30","current":-15.280433,"twenty":-24.971672,"median":-19.022068,"eighty":-16.22453,"marketCap":4807832597},{"date":"2026-02-06","current":-15.542994,"twenty":-24.952303,"median":-18.937078,"eighty":-16.152588,"marketCap":4902849052},{"date":"2026-02-13","current":-15.334427,"twenty":-24.923448,"median":-18.860882,"eighty":-16.099082,"marketCap":4864842470},{"date":"2026-02-20","current":-15.572498,"twenty":-24.905533,"median":-18.847277,"eighty":-16.071561,"marketCap":4933254317},{"date":"2026-02-27","current":-14.952615,"twenty":-24.827654,"median":-18.801141,"eighty":-15.988536,"marketCap":4788829306},{"date":"2026-03-06","current":-13.279596,"twenty":-24.77147,"median":-18.709822,"eighty":-15.892604,"marketCap":4218730579},{"date":"2026-03-13","current":-12.861452,"twenty":-24.760877,"median":-18.616931,"eighty":-15.828013,"marketCap":4104710834},{"date":"2026-03-20","current":-12.157235,"twenty":-24.758022,"median":-18.440891,"eighty":-15.765099,"marketCap":3865269369},{"date":"2026-03-27","current":-12.164275,"twenty":-24.758022,"median":-18.409208,"eighty":-15.692499,"marketCap":3857668052},{"date":"2026-04-02","current":-12.25818,"twenty":-24.73228,"median":-18.399621,"eighty":-15.606124,"marketCap":4180723998},{"date":"2026-04-10","current":-12.412577,"twenty":-24.72344,"median":-18.391406,"eighty":-15.554796,"marketCap":4266032641},{"date":"2026-04-17","current":-12.351427,"twenty":-24.717087,"median":-18.309793,"eighty":-15.461655,"marketCap":4246798950},{"date":"2026-04-24","current":-11.422185,"twenty":-24.709149,"median":-18.216326,"eighty":-15.337994,"marketCap":3927519681},{"date":"2026-04-30","current":-11.117278,"twenty":-24.702871,"median":-18.174743,"eighty":-15.304685,"marketCap":3823657750},{"date":"2026-05-08","current":-10.777891,"twenty":-24.684547,"median":-18.056929,"eighty":-15.189837,"marketCap":3719795820},{"date":"2026-05-15","current":-9.293361,"twenty":-24.617578,"median":-17.965815,"eighty":-15.119492,"marketCap":3215873118},{"date":"2026-05-22","current":-8.991533,"twenty":-24.605712,"median":-17.939574,"eighty":-15.043492,"marketCap":3104317711},{"date":"2026-05-29","current":-10.14843,"twenty":-24.599189,"median":-17.918048,"eighty":-14.961326,"marketCap":3515918696},{"date":"2026-06-05","current":-8.237808,"twenty":-24.571342,"median":-17.89208,"eighty":-14.895383,"marketCap":2858126467},{"date":"2026-06-12","current":-7.644268,"twenty":-24.535606,"median":-17.732128,"eighty":-14.684931,"marketCap":2650402606},{"date":"2026-06-18","current":-6.884404,"twenty":-24.459385,"median":-17.688347,"eighty":-14.384241,"marketCap":2392671147},{"date":"2026-06-26","current":-6.195227,"twenty":-24.397853,"median":-17.672452,"eighty":-13.470121,"marketCap":2142633166},{"date":"2026-07-03","current":-7.179757,"twenty":-24.364887,"median":-17.499062,"eighty":-13.369605,"marketCap":2484992864},{"date":"2026-07-10","current":-8.078806,"twenty":-24.314468,"median":-17.476751,"eighty":-13.262753,"marketCap":2792731918},{"date":"2026-07-17","current":-8.127776,"twenty":-24.232724,"median":-17.419476,"eighty":-13.079412,"marketCap":2819659085},{"date":"2026-07-24","current":-7.604914,"twenty":-24.150839,"median":-17.377721,"eighty":-12.93356,"marketCap":2638862391},{"date":"2026-07-31","current":-7.53517,"twenty":-24.119743,"median":-17.333807,"eighty":-12.87079,"marketCap":2619628700},{"date":"2026-08-07","current":-7.625479,"twenty":-24.07756,"median":-17.320685,"eighty":-12.528428,"marketCap":2656172713},{"date":"2026-08-14","current":-7.417307,"twenty":-24.00283,"median":-17.276309,"eighty":-12.375887,"marketCap":2586931426},{"date":"2026-08-21","current":-10.34776,"twenty":-23.939778,"median":-17.197085,"eighty":-12.303816,"marketCap":2563850996},{"date":"2026-08-28","current":-9.732294,"twenty":-23.880566,"median":-17.053511,"eighty":-12.176647,"marketCap":2411904838},{"date":"2026-09-04","current":-9.627537,"twenty":-23.866484,"median":-17.033052,"eighty":-12.068009,"marketCap":2386901040},{"date":"2026-09-09","current":-5.344387,"twenty":-23.850097,"median":-16.983362,"eighty":-11.991643,"marketCap":1327124672}],"updateTime":1789037582460},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02410\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1134286006","title":"Major Breakthrough at ASCO 2026: TYK MEDICINES-B's Edotinib Achieves 95.5% Intracranial Objective Response Rate, Leading the Frontline Treatment for EGFR Lung Cancer Brain Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=1134286006","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134286006?lang=en_us&edition=fundamental","pubTime":"2026-06-01 10:13","pubTimestamp":1780280012,"startTime":"0","endTime":"0","summary":"A key clinical breakthrough was announced at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. TYK MEDICINES-B (02410), a Hong Kong-listed innovative pharmaceutical company,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09939","159938","BK1161","02410","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192011753","title":"TYK Medicines reports superior interim Phase II data for asandeutertinib versus osimertinib in first-line EGFR-mutant NSCLC with brain metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=1192011753","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192011753?lang=en_us&edition=fundamental","pubTime":"2026-05-31 18:24","pubTimestamp":1780223069,"startTime":"0","endTime":"0","summary":"TYK Medicines (02410.HK) released interim results from the pivotal Phase II ESAONA study comparing asandeutertinib (TY-9591) with osimertinib as first-line therapy for epidermal growth factor...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151955380","title":"Key Phase II ESAONA Study Results for TYK MEDICINES-B's (02410) TY-9591 in First-Line NSCLC Brain Metastases Presented as Late-Breaking Abstract at 2026 ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=1151955380","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151955380?lang=en_us&edition=fundamental","pubTime":"2026-05-31 18:20","pubTimestamp":1780222827,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) announced that the interim analysis results from the pivotal Phase II ESAONA study for its self-developed drug, TY-9591 (mesylate edotinib tablets), versus osimertinib in the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","159938","BK1574","BK1515","02410","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639600295","title":"TYK Medicines says Phase II study shows asandeutertinib beats osimertinib on intracranial response in EGFR-mutant NSCLC with brain metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2639600295","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639600295?lang=en_us&edition=fundamental","pubTime":"2026-05-31 18:11","pubTimestamp":1780222303,"startTime":"0","endTime":"0","summary":"TYK Medicines says Phase II study shows asandeutertinib beats osimertinib on intracranial response in EGFR-mutant NSCLC with brain metastases. TYK Medicines highlighted interim results from its pivotal Phase II ESAONA trial of asandeutertinib in EGFR-mutant NSCLC with brain metastases.Results were already presented as a late-breaking oral abstract at the 2026 ASCO Annual Meeting.The study showed stronger control of brain metastases versus AstraZeneca’s osimertinib, with a manageable safety profile.Systemic disease control also favored asandeutertinib, supporting a potential new first-line positioning in this patient group.An NDA has been accepted in China and placed into a priority review pathway, with longer-term follow-up still ongoing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260531:nNDL3gRqnT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149674578","title":"TYK Medicines Releases 2025 AGM Agenda Covering Profit Distribution, Share Mandates and Board Re-election","url":"https://stock-news.laohu8.com/highlight/detail?id=1149674578","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149674578?lang=en_us&edition=fundamental","pubTime":"2026-05-22 16:45","pubTimestamp":1779439549,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. has issued the proxy form for its 2025 Annual General Meeting scheduled for 2:00 p.m. on 23 June 2026 at 8/F, Building T2, China Eastern Binjiang Center, Xuhui District, Shanghai....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167825735","title":"TYK Medicines to Seek 20% Share Issue Mandate, RMB300 Million Bank Lines and No-Dividend Plan at 23 June AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=1167825735","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167825735?lang=en_us&edition=fundamental","pubTime":"2026-05-22 16:44","pubTimestamp":1779439446,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. (TYK Medicines) released its 2025 AGM circular dated 22 May 2026, detailing resolutions to be tabled on 23 June 2026 in Shanghai. Financial Reporting and Dividend   • The audited...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635776438","title":"Insiders Could Have Profited By Holding onto TYK Medicines Shares Despite 12% Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2635776438","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635776438?lang=en_us&edition=fundamental","pubTime":"2026-05-14 11:15","pubTimestamp":1778728529,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc's (HKG:2410) value has fallen 12% in the last week, but insiders who sold CN¥4.2m worth of stock...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2410/tyk-medicines-shares/news/insiders-could-have-profited-by-holding-onto-tyk-medicines-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2410/tyk-medicines-shares/news/insiders-could-have-profited-by-holding-onto-tyk-medicines-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","MDCO","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169008621","title":"TYK Medicines Posts Stable Share Capital and Maintains Public Float in April 2026 Monthly Return","url":"https://stock-news.laohu8.com/highlight/detail?id=1169008621","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169008621?lang=en_us&edition=fundamental","pubTime":"2026-05-06 17:23","pubTimestamp":1778059403,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. (H-share; HKEX: 02410) filed its Monthly Return for Equity Issuer covering the period ended 30 April 2026, confirming no changes to share capital and continued compliance with...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120304539","title":"TYK Medicines-B 2025年研发推进加速，亏损收窄至3.06亿元，净资产维持正值","url":"https://stock-news.laohu8.com/highlight/detail?id=1120304539","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120304539?lang=en_us&edition=fundamental","pubTime":"2026-04-29 16:59","pubTimestamp":1777453145,"startTime":"0","endTime":"0","summary":"TYK Medicines-B于本年度进一步聚焦癌症领域的差异化创新靶向治疗，专注于小分子抗肿瘤药物的研发与商业化推进，共拥有10项在研新药，其中5款处于临床阶段，4款处于临床前或早期临床阶段。核心产品TY-9591围绕EGFR基因突变相关的非小细胞肺癌展开多项临床试验，涵盖针对脑转移的一线单药治疗、与培美曲塞及顺铂或卡铂联合用药的二、三期试验及EGFR...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"TYK Medicines-B 2025年研发推进加速，亏损收窄至3.06亿元，净资产维持正值","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631560423","title":"TYK Medicines publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2631560423","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631560423?lang=en_us&edition=fundamental","pubTime":"2026-04-29 16:43","pubTimestamp":1777452198,"startTime":"0","endTime":"0","summary":"TYK Medicines annual report for 2025 outlined progress toward first commercialization, led by core oncology asset TY-9591.TY-9591 conditional NDA for first-line treatment of brain metastases in EGFR-mutant lung cancer entered priority review in January 2026, with marketing approval expected in Q3 2026.Enrollment in registrational Phase III trial of TY-9591 in first-line EGFR L858R-mutant NSCLC reached 548 patients in April 2026, with full enrollment expected in Q4 2026 and NDA targeted for 2028.Pipeline execution extended beyond TY-9591, with TY-302 in Phase II for breast cancer, TY-2136b in Phase I in US, TY-1054 dosing first patient in March 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the origina","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL4lSxhd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181264075","title":"TYK MEDICINES-B's (02410) Self-Developed TY-3002 Monotherapy Demonstrates Outstanding Weight Loss Efficacy, Pioneering Next-Generation Oral GLP-1R Small Molecule Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=1181264075","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181264075?lang=en_us&edition=fundamental","pubTime":"2026-04-16 17:13","pubTimestamp":1776330825,"startTime":"0","endTime":"0","summary":"The weight loss sector, a core focus in global innovative drug development, continues to attract leading industry players. Recently, TYK MEDICINES-B (02410) announced the formal nomination of its...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","159938","GLP","02410","TY","BK1515","BK4144","09939","BK1574","BK4590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116554785","title":"TYK Medicines Converts 4.61 Million Unlisted Shares Into H Shares, Registered Capital Rises to RMB 380.07 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1116554785","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116554785?lang=en_us&edition=fundamental","pubTime":"2026-04-08 18:02","pubTimestamp":1775642537,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. (TYK Medicines) reported in its resubmitted Monthly Return for the period ended 31 March 2026 that it completed the conversion of 4.61 million unlisted shares into the same number...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136728831","title":"TYK Medicines Completes 4.61 Million-Share Conversion to H Shares, Expanding Registered Capital to 380.07 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1136728831","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136728831?lang=en_us&edition=fundamental","pubTime":"2026-04-02 16:44","pubTimestamp":1775119481,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. released its Monthly Return on Movements in Securities for March 2026, highlighting a structural change in its share composition: • Share Class Conversion: On 4 March 2026, the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182188038","title":"Stock Track | TYK MEDICINES-B Soars 7.26% Intraday on Strong Annual Results and Upcoming AACR Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=1182188038","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182188038?lang=en_us&edition=fundamental","pubTime":"2026-04-01 12:57","pubTimestamp":1775019445,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B's stock surged 7.26% during intraday trading on Wednesday, driven by the release of its annual financial results and a significant research announcement.The company recently disclosed...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153741167","title":"TYK MEDICINES-B Shares Surge Over 7% Following Annual Report and Key AACR Presentation Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1153741167","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153741167?lang=en_us&edition=fundamental","pubTime":"2026-04-01 12:02","pubTimestamp":1775016153,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) saw its shares rise more than 7%. As of the time of writing, the stock was up 7.07%, trading at HKD 10.9 with a turnover of HKD 30.54 million. On March 31, TYK MEDICINES-B...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","VXUS","09939","BK4588","159992","159938","06978","BK1574","02410","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623720553","title":"TYK Medicines' Loss Narrows in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2623720553","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623720553?lang=en_us&edition=fundamental","pubTime":"2026-03-31 12:39","pubTimestamp":1774931956,"startTime":"0","endTime":"0","summary":"TYK Medicines'  loss attributable to owners narrowed to 299.8 million yuan for 2025, from 387 million yuan a year earlier, according to a Monday Hong Kong bourse filing.Shares of the pharmaceutical company were up nearly 2% in late morning trade on Tuesday.Loss per share shrank to 0.80 yuan from 1.15 yuan a year earlier.The company did not generate revenue in 2025. In 2024, its revenue came in at 107,000 yuan.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02410","MDCO","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623231904","title":"BRIEF-Tyk Medicines FY Loss Attributable Rmb299.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623231904","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623231904?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:57","pubTimestamp":1774868230,"startTime":"0","endTime":"0","summary":"BRIEF-Tyk Medicines FY Loss Attributable Rmb299.8 MillionMarch 30 (Reuters) - TYK Medicines Inc 2410.HK:FY LOSS ATTRIBUTABLE RMB299.8 MILLIONFurther company coverage: 2410.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nFWN40G02L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108363335","title":"TYK MEDICINES-B Reports Annual Results: R&D Expenditure Rises 3.7% to Approximately 244 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1108363335","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108363335?lang=en_us&edition=fundamental","pubTime":"2026-03-30 17:06","pubTimestamp":1774861599,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) has announced its financial results for the fiscal year ended December 31, 2025. The company's research and development costs amounted to approximately 244 million yuan,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","BK1161","02410","BK1515","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124616055","title":"TYK Medicines 2025 Net Loss Narrows 21% to RMB 305.97 Million; NDA for Core Drug TY-9591 Enters Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=1124616055","media":"Bulletin Express","labels":["productRelease","dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124616055?lang=en_us&edition=fundamental","pubTime":"2026-03-30 17:05","pubTimestamp":1774861549,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. reported a consolidated net loss of RMB 305.97 million for 2025, an improvement of 21.1% versus 2024. Loss per share narrowed to RMB 0.80 from RMB 1.15. R&D AND EXPENSES   •...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623909413","title":"Tyk Medicines Inc - FY Loss Attributable RMB299.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2623909413","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623909413?lang=en_us&edition=fundamental","pubTime":"2026-03-30 16:45","pubTimestamp":1774860342,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nFWN40G02L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02410","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":63,"code":"91000000","status":"200"}]}}